NCT05230654 2022-02-09
Efficacy and Safety of Fosaprepitant in Preventing Chemotherapy-induced Vomiting in Children Treated With Medium and High Emetic Chemotherapeutic Drugs
Shanghai Children's Medical Center
Phase NA Unknown
Clinical Trials
5 trialsNCT04873284 2021-05-10
Comparative Study of Fosaprepitant and Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Caner Patients
Shanghai Children's Medical Center
Phase NA Unknown
NCT01504711 2021-04-08
Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy
Barbara Ann Karmanos Cancer Institute
Phase NA Completed
NCT01344304 2021-02-26
Study of Aprepitant / Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients - SENRI Trial
Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group
Phase NA Completed
NCT01490060 2016-04-11
Fosaprepitant in Patients Receiving Ifosfamide-based Regimen
M.D. Anderson Cancer Center
Phase NA Completed